Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $41.82 USD
Change Today -0.42 / -0.99%
Volume 345.0K
As of 8:04 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8-2-337, Road No. 3

Banjara Hills

Hyderabad, 500034


Phone: 91 40 4900 2900

Fax: 91 40 4900 2999

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. The company has a presence in markets, such as the United States, the United Kingdom, and Germany, as well as other primary markets, such as India, Russia, Venezuela, Romania, South Africa, and certain countries of the former Soviet Union. Segments The company operates through three business segments: Global Generics; Pharmaceutical Services and Active Ingredients (PSAI); and Proprietary Products. Global Generics segment This segment consists of the company’s business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the company’s biologics business. India In India, the company’s major therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. The company is also increasing its presence in the niche areas of dermatology, urology, and nephrology. As of March 31, 2015, the company had a total of 260 branded products in India. IMS Health Inc. is a provider of market research to the Indian pharmaceutical industry. Sales, Marketing and Distribution Network: The company generates demand for its products through its 5,176 sales representatives (which include representatives engaged by the company on a contract basis through a service provider) and front line managers, who frequently visit doctors to detail its related product portfolio. The company sells its products primarily through clearing and forwarding agents to approximately 2,500 wholesalers who decide which brands to buy based on demand. The wholesalers pay for the company’s products in an agreed credit period and in turn sell these products to retailers. The company’s clearing and forwarding agents are responsible for transporting its products to the wholesalers. In April 2015, the company entered into a definitive agreement with UCB India Private Limited and other UCB group companies to acquire a select portfolio of products business in the territories of India, Nepal, Sri Lanka, and Maldives. The acquisition is expected to strengthen its presence in the areas of dermatology, respiratory, and pediatric products. Competition: The company’s principal competitors in the Indian market include Cipla Limited; GlaxoSmithKline Pharmaceuticals Limited; Cadila Healthcare Limited; Sun Pharmaceutical Industries Limited; Alkem Limited; Mankind Pharma Limited; Pfizer Limited; Abbott India; Lupin Limited; Aristo Pharma Limited; Intas Pharma; Sanofi India Limited; and Emcure Pharmaceuticals Limited. Russia and other Countries of the former Soviet Union Russia: The company’s major four brands include Nise, Omez, Ketorol, and Cetrine. The company’s strategy in Russia is to focus on the gastro-intestinal, pain management, anti-infectives, respiratory, oncology, and cardiovascular therapeutic areas. The company’s focus is on building major brands in these therapeutic areas in prescription, OTC and hospital sales. Ibuclin, a cold and flu product, was switched from prescription to OTC during the year ended March 31, 2014. Other Countries of the former Soviet Union: The company operates in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus, and Uzbekistan. Sales, Marketing and Distribution Network: The company’s marketing and promotion efforts in its Russian prescription division is driven by a team of 284 medical representatives and 48 managers to detail its products to doctors in 77 cities in Russia. The company’s Russian OTC division has 226 medical representatives and 40 managers, and is focused on establishing a network of relationships with key pharmacy chains and individual pharmacies. The company’s Russian hospital division has 41 hospital specialists and 17 key account managers, and is focused on expanding its presence in hospitals and institutes. Competition: The company’s principal competitors in th


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $41.82 USD -0.42

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 661.95 INR 0.00
Cipla Ltd/India 528.60 INR 0.00
Croda International PLC 2,726 GBp +30.00
Lonza Group AG SFr.138.10 CHF +2.30
Symrise AG €55.52 EUR +0.396
View Industry Companies

Industry Analysis


Industry Average

Valuation RDY Industry Range
Price/Earnings 19.3x
Price/Sales 3.0x
Price/Book 3.7x
Price/Cash Flow 19.3x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DOCTOR REDDY'S LAB-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at